Mechanisms behind hyperglycemia-associated breast cancer risk and progression

高血糖相关乳腺癌风险和进展背后的机制

基本信息

  • 批准号:
    9113516
  • 负责人:
  • 金额:
    $ 35.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-21 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Epidemiologic evidence suggests that women with diabetes have increased risk of breast cancer and that diabetes may dramatically increase mortality in patients with cancer. Importantly, African-American and Hispanic/Latina women are disproportionately affected by diabetes and its complications. Concurrently, these women have worst outcome from breast cancer. Diabetes and cancer share many risk factors, but potential biologic links between the two diseases are incompletely understood. Our preliminary studies have provided new insights into how high glucose (HG) functions in breast epithelial cells. Exposure of cultured transformed (MCF-7) and normal (MCF-10A) breast epithelial cells to clinically relevant levels of glucose dramatically suppresses the tumor suppressor p53 acetylation, and, consequently, additively promotes tumor cell proliferation and abrogates DNA damage-induced apoptosis. Importantly, activation of nuclear phosphatase PP2Cd plays a role in this process. In addition, we for the first time demonstrate that BRAC1 forms a complex with p300 and p53, and an increased phosphorylation of BRAC1 by DNA damage enhances the recruitment of p53 to p300 and facilitates subsequent p53 acetylation. Upon activation by HG, PP2Cd dephosphorylates BRAC1 and inhibits its up-regulatory effect on p53 acetylation. These results may not only provide explanation for increased epithelial proliferation and tumorigenesis by hyperglycemia, but also increased breast cancer risk by diabetes. Based on these results we hypothesize that hyperglycemia, via a pathway that involved in PP2Cd activation, suppresses the tumor suppressor BRCA1 and p53 function and inhibits DNA damage-induced apoptosis and cell cycle arrest, inducing proliferation in the epithelium and the initiation and development of breast cancer. This hypothesis will be tested in three specific aims: (1) To explore the mechanisms underlying HG-induced PP2Cd activation; (2) To investigate the molecular mechanism by which PP2Cd dephosphorylates BRAC1 and antagonizes p53 acetylation in breast epithelial cells; (3) To characterize the effects of hyperglycemia on the development and chemotherapy of breast cancer in vivo using streptozotocin (STZ)-induced or high fat diet/STZ-induced diabetic nude mice bearing MCF-7 cells and breast cancer specimens from patients with or without diabetes. These studies set the stage for investigating this novel mechanism connecting diabetes and breast cancer with a goal of defining a new pathway and providing additional targets for therapy. Breast cancer in particular affects a large sector of African-American and Hispanic women and constitutes a significant financial burden for the society. Thus, studying the influence of hyperglycemia on oncogenic signaling networks is a novel question with considerable translational implications and would be a significant step in shedding light on this health disparity.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yong Wu其他文献

Yong Wu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yong Wu', 18)}}的其他基金

A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer
一种治疗糖尿病相关乳腺癌的新型代谢重编程策略
  • 批准号:
    10409714
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer
一种治疗糖尿病相关乳腺癌的新型代谢重编程策略
  • 批准号:
    10615233
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
Mechanisms behind hyperglycemia-associated breast cancer risk and progression
高血糖相关乳腺癌风险和进展背后的机制
  • 批准号:
    8856136
  • 财政年份:
    2015
  • 资助金额:
    $ 35.88万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了